CGAS and cancer: Some limitations of targeting cGAS/STING in cancer exist, including evidence of cGAS/STING silencing or loss-of-function mutations in certain tumors (35, 36) and cGAS/STING-driven IL-6-dependent survival of chromosomally instable cancers (37).